Insider Cluster (2 insiders) ·Filed Aug 17, 2026

DYN

Dyne Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed1mo ago
Insider cluster: 2 insiders, $2.6M total
Actionable Insight ▼ Bearish

The director's selling of ~1.4% of the company's float in two days is the standout signal. While cluster sells are often liquidity-driven, the magnitude here is unusual and not explained by routine 10b5-1 plans (no evidence provided). Monitor for any near-term news (e.g., upcoming data readout, FDA interaction) that could have prompted the sale. If the stock weakens, the selling pressure could accelerate given the prior month's $72M in sales.

DirectionBearish
Confidencemedium
Horizondays
Latest settled — T+20d
DYN ▼ -31.55% at T+20d
SHORT call ✓ call won +31.55% · α vs SPY +29.57% · entry $26.15 → $17.90
Next anchor: T+60d in 5w
Latest observation: T+31 +59.15% FF3 residual α
Entry anchored
Aug 14, 04:39 PM ET
via 1-min bar
T+1d
-0.57%
call +0.57% · α -0.10%
$26.00
settled 7w ago
T+5d
-0.61%
call +0.61% · α -0.58%
$25.99
settled 6w ago
T+20d
-31.55%
call +31.55% · α +29.57%
$17.90
settled 18d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

Director Jason P. Rhodes sold ~$65.2M worth of DYN shares (1.4% of market cap) in a cluster over two days, while CEO John Cox made a minor $131K sale. This is the largest insider sale at Dyne in the current reporting window and occurs against a backdrop of heavy institutional ownership and a bullish analyst consensus. The sheer size and concentration of the sales, particularly the director's, warrant attention despite the academic literature discounting the predictive power of cluster sales.

Key Financial Metrics

Direction
selling
Total Value
$65.3M
Insiders
2

Key Facts

  • Director Jason P. Rhodes sold ~2.5M shares for ~$65.2M on August 13-14, 2026.
  • CEO John Cox sold 4,986 shares for ~$131K on August 13, 2026.
  • Total insider sales of ~$65.3M represent ~1.4% of DYN's $4.8B market cap.
  • All sales were open-market transactions (code S).
  • Prior 30-day insider activity: 9 sells totaling $72.0M.
  • Analyst consensus is 90% bullish (19 Buy/7 Strong Buy, 2 Hold).

Financial Impact

~$65.3M in insider selling (1.4% of $4.8B market cap)

insider ownershipmarket sentiment

Risk Factors

  • Potential upcoming negative catalyst (e.g., clinical data miss, regulatory setback) that motivated the large insider sale.
  • Further insider selling by remaining large holders if the stock declines.
  • High institutional ownership (BlackRock, Fidelity, State Street) could exacerbate sell-off if they reduce positions.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-DYN-1787034007865
44 reports for DYN
Performance horizon
86% Hit rate 12 of 14 directional calls best @ T+60▲ +46.36%May 20, 2026
Filters
Rows
Reports for DYN — sortable, filterable
TypeNow
Aug 17, 2026
6w ago
Insider Cluster
BEARISH ★ 6/10
$26.15 $17.90▲ +31.55%▲ +29.57%$15.20 (+41.87%)
Aug 14, 2026
6w ago
144
NEUTRAL ★ 4/10
$26.15 $18.52▼ −29.18%▼ −27.65%$15.20 (−41.87%)
Aug 13, 2026
7w ago
144
BEARISH ★ 6/10
$25.70 $18.52▲ +27.94%▲ +25.95%$15.20 (+40.86%)
Aug 13, 2026
7w ago
144
NEUTRAL ★ 2/10
$25.70 $18.52▼ −27.94%▼ −25.95%$15.20 (−40.86%)
Aug 13, 2026
7w ago
144
NEUTRAL ★ 2/10
$25.70 $18.52▼ −27.94%▼ −25.95%$15.20 (−40.86%)
Jul 29, 2026
9w ago
Press Release
BULLISH ★ 7/10
$25.73 $26.09▲ +1.40%▼ −2.57%$15.20 (−40.92%)
Jul 22, 2026
10w ago
Press Release
BEARISH ★ 6/10
$23.21 $26.78▼ −15.38%▼ −12.48%$15.20 (+34.51%)
Jul 20, 2026
10w ago
8-K
BULLISH ★ 7/10
$23.45 $26.15▲ +11.51%▲ +7.39%$15.20 (−35.18%)
Jun 30, 2026
13w ago
Insider Cluster
NEUTRAL ★ 5/10
$21.79 $25.10▲ +15.19%▲ +17.38%$15.20 (−30.24%)
Jun 29, 2026
13w ago
144
BEARISH ★ 4/10
$22.21 $25.63▼ −15.40%▼ −16.43%$15.20 (+31.56%)
Showing 10 of 44

US Market Status

Market Closed — Opens Mon (65h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Aug 18, 2026